Celonic, a Basel, Switzerland-headquartered contract development and manufacturing organization, has completed its previously announced acquisition of a biomanufacturing facility in Heidelberg, Germany from Glycotope, a Berlin, Germany-headquartered biotechnology company.

Glycotope focuses on developing immuno-oncological products for treating various cancer types using its GlycoBody and GlycoExpress technologies. Glycotope has currently two products in advanced clinical development. The company’s additional pipeline includes preclinical antibody biopharmaceuticals for various oncological indications.

Celonic says the acquisition is expected to accelerate investment in capacity for late-stage compounds and commercial supply.

Source: Celonic